Charles River Laboratories International, Inc. (CRL)
Charles River Laboratories: Changing Economics Reduces Compounding Ability (Rating Downgrade)
Charles River came in with another set of soft numbers, indicating a period of weaker business ahead for the company. Management is scaling back CapEx into the business and focusing on buybacks, suggesting there's no viable reinvestment opportunities to grow. The intrinsic worth of the business is $215–$223/share under present conditions, in my opinion, warranting a hold.
Why Charles River (CRL) International Revenue Trends Deserve Your Attention
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Weak biopharma market challenges persist, impacting CRL's revenue and bottom-line growth. Cost streamlining initiatives in place to generate $150 million in annualized cost savings by FY25. Growth projection includes a 3% revenue decline in FY24, with a fair value of $220 per share based on DCF analysis.
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.
Charles River Laboratories International Inc (CRL) Q2 2024 Earnings Call Transcript
Charles River Laboratories International Inc (NYSE:CRL ) Q2 2024 Results Conference Call August 7, 2024 9:00 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relations Jim Foster - CEO, President & Chairman Flavia Pease - Corporate Executive VP & CFO Conference Call Participants Matt Sykes - Goldman Sachs Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Dave Windley - Jefferies Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Casey Woodring - JPMorgan Luke Sergott - Barclays Michael Ryskin - Bank of America Max Smock - William Blair Operator Ladies and gentlemen, thank you for standing by, and welcome to Charles River Laboratories Second Quarter 2024 Earnings Conference Call. Just a reminder, this call is being recorded.
Charles River Labs Says It Expects Sales To Fall, Sending Its Stock Tumbling
Shares of Charles River Laboratories (CRL) tumbled over 12% in intraday trading Wednesday after the company said it expects to post a decline in sales for the full fiscal year, instead of growth.
Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Charles River Laboratories Stock Sinks As It Warns Of Continued Biotech Demand Slump, Lowers Forecast
Charles River Laboratories International Inc CRL reported second-quarter 2024 revenue of $1.03 billion on Wednesday, a decrease of 3.2% year over year, beating the consensus of $1.024 billion.
Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.69 per share a year ago.
Charles River cuts 2024 forecast as funding crunch among biotech clients persists
Charles River Laboratories trimmed its annual forecast on Thursday, as it no longer expects demand for its drug discovery and development services to improve in the second half of the year, sending its shares down 15% in premarket trading.
Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings
Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.
